Sana Biotechnology, Inc.

Sana Biotechnology, Inc. is a clinical-stage biopharmaceutical company dedicated to developing engineered cells as medicines to address the underlying causes of various diseases. The company's mission is to "change the possible for patients through engineered cells", aiming to repair and control genes or replace missing or damaged cells. Headquartered in Seattle, Washington, Sana Biotechnology also maintains operations in Cambridge, Massachusetts, and South San Francisco, California.

Sana Biotechnology's core innovation revolves around its proprietary Hypoimmune (HIP) platform, designed to enable cell transplants to evade immune detection and function without the need for lifelong immunosuppression. The company also leverages fusogen technology for in vivo delivery of genetic material and ex vivo cell engineering. Its pipeline focuses on significant unmet medical needs across therapeutic areas including oncology (B-cell malignancies), autoimmune diseases (B-cell mediated conditions like lupus nephritis and systemic lupus erythematosus), and Type 1 Diabetes (pancreatic islet cell therapies). Key programs include SC451 for Type 1 Diabetes, SG293 for in vivo CAR T cell therapy targeting B-cell cancers and autoimmune diseases, and UP421, a primary islet cell therapy for Type 1 Diabetes.

Led by President and CEO Steve Harr, MD, since September 2018, Sana Biotechnology has recently announced a strategic collaboration with the Mayo Clinic to advance SC451 for Type 1 Diabetes. In April 2026, the company also revealed plans to present preclinical data for its SG293 in vivo CAR T candidate at the American Society of Gene & Cell Therapy Annual Meeting in May 2026. Earlier in March 2026, Sana reported continued positive clinical results through 14 months for its UP421 program in Type 1 Diabetes, demonstrating sustained cell survival and function without immunosuppression. The company's pipeline was refocused in November 2025 to prioritize SC451 and SG293, optimizing resource allocation.